FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 367 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR What Do You Put In Your Pocket? April 28, 2021 Five Questions with…Debra. March 31, 2022 Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... January 28, 2022 FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed... January 22, 2021 Load more HOT NEWS What Survivors Should Know When Transitioning From Cancer Care to Primary... ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland The Cancer Moonshot: A Midpoint Progress Update Marc Cuban’s Cost Plus Drug Company: A Potential Gold Mine for...
